CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV): Nasdaq/NYSE listing notice — Clover Health receives Nasdaq delisting notice for bid price below $1.00

CLOVER HEALTH INVESTMENTS, CORP. /DE

Nasdaq notified Clover on April 20, 2023 that CLOV closed below $1.00 for 30 consecutive business days.
Company has 180 calendar days, until October 17, 2023, to regain compliance by closing at $1.00+ for 10 consecutive days.
May seek stockholder approval to effect a reverse stock split to regain compliance.
If not compliant by Oct 17, may transfer to Nasdaq Capital Market for an additional 180-day cure period.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

CLOVER HEALTH INVESTMENTS, CORP. /DE received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

April 20, 2023, Clover Health Investments, Corp. (the “Company”) received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s Class A common stock (the “Common Stock”) had closed below the $1.00 per share minimum bid price requirement for continued inclusion on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Notice has no immediate effect on the listing of the Common Stock, which continues to trade o

View on SEC.gov

Browse all listing & compliance notices →

CLOVER HEALTH INVESTMENTS, CORP. /DE filing history →

Source: SEC EDGAR

accession 0001801170-23-000024

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.